First Oral Treatment for Severe Hidradenitis Suppurativa Nears FDA Approval

A new oral treatment for moderate to severe hidradenitis suppurativa (HS) is under review by regulators. Povorcitinib, a JAK1 inhibitor, could become the first pill-based option for patients with this chronic inflammatory skin disease. Over 150,000 people in the U.S. alone suffer from severe forms of HS, which causes painful lesions and significantly impacts quality of life. Povorcitinib has shown promising results in clinical trials. By Week 54, up to 20% of patients achieved complete resolution of inflammatory lesions, while 71.4% saw at least a 50% reduction in abscesses and nodules. Another 57% reached a 75% improvement, and 29% experienced full clearance of symptoms.

The drug also improved patients' daily lives, reducing skin pain and fatigue over the same period. Its safety profile remained consistent with earlier studies, with no unexpected side effects reported through 54 weeks of treatment. Povorcitinib works by targeting the JAK/STAT pathway, which plays a key role in driving inflammation in HS. Currently, the U.S. Food and Drug Administration and the European Medicines Agency are reviewing applications for its approval. If successful, it would offer a convenient alternative to injectable or intravenous therapies. Beyond HS, the drug is also being tested for nonsegmental vitiligo, prurigo nodularis, and moderate to severe asthma. However, no official timelines for regulatory decisions have been announced yet.

The potential approval of povorcitinib could change how moderate to severe HS is managed. As the first oral treatment option, it may provide relief for thousands of patients struggling with painful symptoms. Regulatory reviews are ongoing, but the drug's strong clinical performance suggests it could soon become a standard therapy.